Table 2

 Effects of treatment with atorvastatin or no statin (control group) on forearm blood flow, components of the thrombosis–fibrinolysis system, and serum lipids in patients with heart failure at baseline and after four weeks

Atorvastatin treated groupControl group*
BeforeAfterp ValueBeforeAfter
Data are mean (SD) or median (25th–75th percentile).
*All differences between values before and after were not significant in the control group.
NTG%, forearm vasodilatory response to nitrate; RH%, forearm vasodilatory response to reactive hyperaemia.
Baseline flow 1 (ml/100 ml tissue/min)4.41 (1.35)3.53 (1.4)NS3.86 (1.42)3.85 (1.16)
Reactive hyperaemia flow 1 (ml/100 ml tissue/min)6.35 (2.23)6.17 (2.11)NS5.78 (2.29)5.52 (2.15)
RH% (%)42.44 (18.9)83.7 (36.1)<0.0148.41 (19.7)45.18 (21.45)
Baseline flow 2 (ml/100 ml tissue/min)4.39 (1.11)4.18 (1.76)NS3.44 (0.77)3.54 (0.81)
Flow after nitrate (ml/100 ml tissue/min)7.18 (1.85)6.37 (2.2)NS5.96 (1.71)5.75 (1.53)
NTG (%)59.0 (38.5–92.0)60.5 (43.5–80.1)NS63.0 (37.0–94.5)64.0 (30.0–96.1)
Tissue plasminogen activator (ng/ml)11.68 (8.60–20.95)10.30 (8.65–15.12)<0.0513.04 (9.70–18.9)11.0 (8.35–17.55)
Antithrombin III (%)81.7 (11.37)73.5 (13.8)<0.0185.1 (17.9)87.8 (13.4)
Protein C (%)88.3 (26.9)63.9 (25.0)<0.0183.9 (23.5)83.6 (18.2)
Factor V (%)126.2 (33.4)94.9 (29.8)<0.01130.7 (40.9)125.1 (32.8)
Factor VII (%)77.45 (48.0–106.1)67.8 (47.6–81.8)NS72.9 (41.6–99.8)66.0 (33.7–98.0)
von Willebrand factor (%)130.4 (99.7–168.7)102.8 (58.8–169.7)NS119.9 (100.5–181.6)132.0 (90.3–164.8)
Plasminogen activator inhibitor 1 (IU/l)3.10 (2.15–4.40)1.90 (0.75–3.0)<0.052.45 (1.27–3.70)3.15 (2.32–4.10)
Protein S (%)92.86 (20.4)95.3 (32.6)NS100.1 (27.4)95.7 (20.8)
Cholesterol (mmol/l)5.22 (0.58)3.99 (0.82)<0.014.96 (0.87)4.91 (0.90)
Triglycerides (mmol/l)1.37 (0.35)1.08 (0.25)<0.011.37 (0.30)1.38 (0.30)
HDL (mmol/l)0.76 (0.15)0.80 (0.13)<0.010.79 (0.19)0.75 (0.12)